Curious about Lilly (LLY) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Core Insights - Eli Lilly (LLY) is expected to report quarterly earnings of $5.15 per share, reflecting a significant increase of 106.8% year-over-year, with revenues projected at$ 13.48 billion, up 44.1% from the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.5% in the last 30 days, indicating a reassessment by analysts [2] - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [3] Key Metrics Forecast - Analysts predict 'Net Sales- Cyramza' to be $258.19 million, a year-over-year increase of 1.8% [5] - 'Net Sales- Humalog' is expected to reach$ 590.93 million, indicating a substantial increase of 61.2% from the prior year [5] - 'Net Sales- Forteo' is forecasted at $97.33 million, reflecting a decrease of 16.4% year-over-year [6] - 'Net Sales- Erbitux' is estimated at$ 153.10 million, showing a slight increase of 1.9% from the previous year [6] Geographic Revenue Projections - 'Net Sales- International-Humalog' is expected to be $212.76 million, up 6.9% year-over-year [7] - 'Geographic Revenue- United States' is projected to reach$ 9.48 billion, indicating a year-over-year increase of 46.9% [8] - 'Net Sales- Diabetes- Mounjaro -Outside U.S.' is forecasted at $1.08 billion, representing a remarkable increase of 978.2% from the prior year [9] Stock Performance - Shares of Eli Lilly have returned +3.7% over the past month, outperforming the Zacks S&P 500 composite, which increased by +2.7% [9]